Diagenode Introduces Epigenetics Services

Share Article

New ChIP-seq and RRBS services streamline research workflows.

Diagenode, a leading global provider of complete solutions for epigenetics research, today announced the launch of its new epigenetics services offering. The services include both ChIP-sequencing and reduced representation bisulfite sequencing (RRBS).

“The new services offering is perfect for both newcomers to epigenetics as well as high-throughput labs that want to utilize Diagenode’s long history of expertise in ChIP-seq or RRBS,” stated Geoffrey Berguet, Product Manager of the new services platform. “Diagenode is well-equipped to support epigenetics researchers as we offer customized support and provide results within six to eight weeks.” The services include full sample preparation, sequencing, and bioinformatics support.

Diagenode has been a long standing official partner of the International Human Epigenome Consortium (IHEC) and the BLUEPRINT epigenome project, engaging in numerous collaborations to develop standardized products for chromatin immunoprecipitation and bisulfite sequencing.

“The new services are a natural extension of our epigenetics product expertise,”Geoffrey Berguet added. “Our latest offering for RRBS, in addition to providing a full service workflow, also provides eight times more coverage than standard technologies. Both our ChIP-seq and RRBS services are very cost-efficient and meet the highest quality standards. We are confident that our customers will be pleased with our new offering.”

For more information about Diagenode’s epigenetics services, please visit

ChIP-seq service: https://www.diagenode.com/categories/chip-seq-service
RRBS service:https://www.diagenode.com/categories/rrbs-service

About Diagenode
Diagenode is a leading provider of complete solutions for epigenetics research. The company has developed a comprehensive approach to gain new insights into epigenetics studies, offering innovative shearing and automation instruments, reagent kits, high quality antibodies, and services to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company’s latest innovations include a unique, full automation system, a reduced representation bisulfite sequencing (RRBS) kit providing eight times more coverage than standard technologies, ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Didier Allaer
Diagenode, Inc.
+1 8587747501
Email >
Visit website